Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-27T22:37:49.803Z Has data issue: false hasContentIssue false

Second-Generation (Atypical) Antipsychotics

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 133 - 184
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Organon Inc. LLC. (2013). Saphris Package Insert. Roseland, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Asenapine Protocol. Sacramento, California.Google Scholar
Bishara, D., Taylor, D. (2008). Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs, 68, 2269–2292.CrossRefGoogle ScholarPubMed
Vieta, E., Sanchez-Moreno, J. (2008). Acute and long-term treatment of mania. Dialogues Clin Neurosci, 10, 165–179.CrossRefGoogle ScholarPubMed
Friberg, L. E., de Greef, R., Kerbusch, T., et al. (2009). Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther, 86, 84–91.CrossRefGoogle ScholarPubMed

References

Jazz Pharmaceuticals Inc. Fazaclo Package Insert. Palo Alto, California.Google Scholar
HLS Therapeutics (U.S.) Inc. (2019). Clozaril Package Insert. Rosemont, Pennsylvania.Google Scholar
Meyer, J. M. (2019). The Clozapine Handbook: Stahl’s Handbooks. New York: Cambridge University Press.CrossRefGoogle Scholar
TruPharma LLC. (2020). Versacloz Package Insert. Tampa, Florida.Google Scholar
Remington, G., Agid, O., Foussias, G., et al. (2013). Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl), 225, 505–518.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Clozapine Protocol. Sacramento, California.Google Scholar
De Berardis, D., Rapini, G., Olivieri, L., et al. (2018). Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf, 9, 237–256.CrossRefGoogle ScholarPubMed
Maguire, G. A. (2002). Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm, 59, S4–11.CrossRefGoogle ScholarPubMed
Solmi, M., Murru, A., Pacchiarotti, I., et al. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag, 13, 757–777.CrossRefGoogle ScholarPubMed
Jin, H., Meyer, J. M., Jeste, D. V. (2002). Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry, 14, 59–64.CrossRefGoogle ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res, 12, 362–368.CrossRefGoogle Scholar
Howland, R. H. (2010). Potential adverse effects of discontinuing psychotropic drugs. J Psychosoc Nurs Ment Health Serv, 48, 11–14.Google ScholarPubMed
Lally, J., Malik, S., Krivoy, A., et al. (2017). The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. J Clin Psychopharmacol, 37, 600–604.CrossRefGoogle ScholarPubMed
Lally, J., Malik, S., Whiskey, E., et al. (2017). Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol, 37, 441–446.CrossRefGoogle ScholarPubMed
Andres, E., Zimmer, J., Mecili, M., et al. (2011). Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol, 4, 143–151.CrossRefGoogle ScholarPubMed

References

Vanda Pharmaceuticals Inc. (2009). Fanapt Package Insert. Washington, D.C.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Iloperidone Protocol. Sacramento, California.Google Scholar
Stahl, S. M. (2002). Antipsychotic Agents, 2nd ed. New York: Cambridge University Press.Google Scholar
Remington, G. J. (2003). Antipsychotics, 13th ed. Toronto: Hogrefe and Huber Co.Google Scholar
Kane, J. M., Lauriello, J., Laska, E., et al. (2008). Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol, 28, S29–35.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res, 12, 362–368.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Asenapine Protocol. Sacramento, California.Google Scholar

References

Intra-cellular Therapies, I. (2019). Caplyta (Lumateperone) Package Insert. Towson, Maryland.Google Scholar
Lexicomp. Lumateperone: Drug Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdfGoogle Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res, 12, 362–368.CrossRefGoogle Scholar
Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 161, 1334–1349.CrossRefGoogle ScholarPubMed

References

Sunovion Pharmaceuticals Inc. Latuda (Lurasidone) Package Insert. Fort Lee, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Lurasidone Protocol. Sacramento, California.Google Scholar
Nakamura, M., Ogasa, M., Guarino, J., et al. (2009). Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry, 70, 829–836.CrossRefGoogle ScholarPubMed
Cucchiaro, J., P. A., et al. (2010). Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. New Orleans, LA: American Psychiatric Association.Google Scholar
Solmi, M., Murru, A., Pacchiarotti, I., et al. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag, 13, 757–777.Google Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res, 12, 362–368.CrossRefGoogle Scholar
Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 161, 1334–1349.Google Scholar

References

Janowsky, D. S., Barnhill, L. J.. Davis, J. M. (2003). Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry, 64, 1258–1265.Google Scholar
Keck, P. E. Jr. (2005). The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry, 66 Suppl. 3, 5–11.Google ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Olanzapine Protocol. Sacramento, California.Google Scholar
Eli Lilly and Company. (2019). Zyprexa Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020592s051,021086s030,021253s036lbl.pdf (last accessed November 7, 2020).Google Scholar
Eli Lilly and Company. (2019). Zyprexa Relprevv Package Insert. Indianapolis, Indiana.Google Scholar
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res, 12, 362–368.Google Scholar
Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., et al. (1999). Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet, 37, 177–193.CrossRefGoogle ScholarPubMed
Baker, R. W., Kinon, B. J., Maguire, G. A., et al. (2003). Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol, 23, 342–348.CrossRefGoogle ScholarPubMed
Botts, S., Littrell, R., de Leon, J. (2004). Variables associated with high olanzapine dosing in a state hospital. J Clin Psychiatry, 65, 1138–1143.Google Scholar

References

Janssen Pharmaceuticals Inc. (2019). Invega Package Insert. Titusville, New Jersey.Google Scholar
Janssen Pharmaceuticals Inc. (2019). Invega Sustenna Package Insert. Titusville, New Jersey.Google Scholar
Janssen Pharmaceuticals Inc. (2019). Invega Trinza Package Insert. Titusville, New Jersey.Google Scholar
Kane, J., Canas, F., Kramer, M., et al. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res, 90, 147–161.Google Scholar
Kramer, M., Simpson, G., Maciulis, V., et al. (2007). Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol, 27, 6–14.CrossRefGoogle ScholarPubMed
Meltzer, H. Y., Bobo, W. V., Nuamah, I. F., et al. (2008). Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry, 69, 817–829.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Paliperidone Protocol. Sacramento, California.Google Scholar
Nasrallah, H. A. (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry, 13, 27–35.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRefGoogle Scholar

References

AstraZeneca Pharmaceuticals LP. (2020). Seroquel Package Insert. Wilmington, Delaware.Google Scholar
AstraZeneca Pharmaceuticals LP. (2020). Seroquel XR Package Insert. Wilmington, Delaware.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Quetiapine Protocol. Sacramento, California.Google Scholar
DeVane, C. L., Nemeroff, C. B. (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet, 40, 509–522.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRefGoogle Scholar
Citrome, L. (2017). Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol, 37, 138–147.Google Scholar

References

Indivior Inc. (2019). Perseris Package Insert. North Chesterfield, Virginia.Google Scholar
Janssen Pharmaceuticals Inc. (2020). Risperdal Package Insert. Titusville, New Jersey.Google Scholar
Janssen Pharmaceuticals Inc. (2020). Risperdal M-tab Package Insert. Titusville, New Jersey.Google Scholar
Janssen Pharmaceuticals Inc. (2020). Risperdal Consta Package Insert. Titusville, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Risperidone Protocol. Sacramento, California.Google Scholar
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google ScholarPubMed
Haddad, P. M., Anderson, I. M. (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62, 1649–1671.CrossRefGoogle ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res, 12, 362–368.Google Scholar
Jin, H., Meyer, J. M., Jeste, D. V. (2002). Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry, 14, 59–64.CrossRefGoogle ScholarPubMed
Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 161, 1334–1349.Google Scholar
Meyer, J. M. (2017). Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr, 22, 14–28.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2018). Converting oral to long-acting injectable antipsychotics: a guide for the perplexed – CORRIGENDUM. CNS Spectr, 23, 186.CrossRefGoogle ScholarPubMed

References

Pfizer Inc. (2020). Geodon Package Insert. New York, New York.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: Paliperidone Protocol. Sacramento, California.Google Scholar
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394, 939–951.CrossRefGoogle ScholarPubMed
Leucht, S., Crippa, A., Siafis, S., et al. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry, 177, 342–353.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry, 62 Suppl. 27, 27–34; discussion 40–41.Google Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRefGoogle Scholar
Aronow, W. S., Shamliyan, T. A. (2018). Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med, 6, 147.CrossRefGoogle ScholarPubMed
Beach, S. R., Celano, C. M., Sugrue, A. M., et al. (2018). QT prolongation, Torsades de Pointes, and psychotropic medications: a 5-year update. Psychosomatics, 59, 105–122.CrossRefGoogle ScholarPubMed
Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×